Search Results 21-30 of 34296 for Two-phase

  1. A Phase 1b/2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma - Mayo Clinic

    About this study. This is a Phase 1b/2, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of B-701 plus docetaxel versus ...

  2. Mayo Clinic Comprehensive Cancer Center — Research

    The purpose of this two-phase study is to compare CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to nivolumab monotherapy administered to ...

  3. A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer - Mayo Clinic

    A Phase 2, 2 part trial to evaluate the safety and efficacy of galeterone in castration resistant prostate cancer (CRPC) patients. Participation eligibility.

  4. Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma - Mayo Clinic

    Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma ... two prior pulmonary relapses. Participation eligibility. Participant eligibility ...

  5. A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis - Mayo Clinic

    PRM-151 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is ...

  6. A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis - Mayo Clinic

    About this study. The purpose of trhis study is to evaluate CPI-0610 in patients who have both received JAK inhibitors, such as ruxolitinib (Arms 1 and 2), ...

  7. A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors - Mayo Clinic

    ... Phase 2 dose for evaluation in these patients. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and ...

  8. Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    Study ACT16970 consists of 2 parts (A and B) as follows: Part A is a 24 week, double blind, placebo controlled part, preceded by a screening period of up to 4 ...

  9. Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies - Mayo Clinic

    Phase 2 (stage 1): To evaluate the activity of single-agent Isatuximab at different doses/schedules and to select dose and regimen to further evaluate the ...

  10. A Phase 2, Multicenter, Randomized Study of AP26113 - Mayo Clinic

    The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of AP26113 in patients with anaplastic lymphoma kinase (ALK)- ...